SEC-sourced researchBeta

XFOR

X4 Pharmaceuticals, Inc

US markets

Data passport

CIK: 0001501697
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Oct 7, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 8:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

XFOR · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	0.0000	Mar 17, 2026
December 2024	2,557,000.0000	Mar 17, 2026
December 2025	35,113,000.0000	Mar 17, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	35,113,000.0000	-79,199,000.0000	-85,618,000.0000	290,461,000.0000	104,171,000.0000	Mar 17, 2026
December 2024	2,557,000.0000	-37,450,000.0000	-130,901,000.0000	146,447,000.0000	124,298,000.0000	Mar 17, 2026
December 2023	0.0000	-101,167,000.0000	-96,512,000.0000	—	—	Mar 17, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$35.11M	December 2025	Mar 17, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$2.56M	December 2024	Mar 17, 2026	10-K
Net incomeNetIncomeLoss	-$79.2M	December 2025	Mar 17, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$85.62M	December 2025	Mar 17, 2026	10-K
Total assetsAssets	$290.46M	December 2025	Mar 17, 2026	10-K
Total liabilitiesLiabilities	$104.17M	December 2025	Mar 17, 2026	10-K

New filings

Explore methodology ↗